Juniper Pharmaceuticals, Inc. Sustainability Profile
Juniper Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2004, the company has established itself as a leader in developing innovative therapeutics, particularly in women's health and reproductive medicine. With a focus on unique drug delivery systems, Juniper's core products include specialised formulations that address unmet medical needs, setting them apart in a competitive market. The company has achieved significant milestones, including successful partnerships and advancements in clinical trials, which have bolstered its market position. Juniper Pharmaceuticals is recognised for its commitment to improving patient outcomes through cutting-edge research and development, making it a notable entity in the biopharmaceutical landscape.
DitchCarbon Score
How does Juniper Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Juniper Pharmaceuticals, Inc.'s score of 45 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Juniper Pharmaceuticals, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Catalent, Inc., and therefore, any climate commitments or emissions data may be inherited from its parent organisation. As of now, Juniper Pharmaceuticals has not established any documented reduction targets or climate pledges. The absence of specific initiatives or targets suggests that the company may still be in the early stages of developing its climate strategy. For context, emissions data and reduction initiatives may be cascaded from Catalent, Inc., which is responsible for setting the broader corporate sustainability framework. However, without specific data from Juniper Pharmaceuticals, it is challenging to provide a detailed overview of their carbon footprint or climate commitments. In summary, while Juniper Pharmaceuticals, Inc. does not currently report emissions data or reduction targets, its relationship with Catalent, Inc. may influence its future climate initiatives and commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 61,000,000 | - | - | 00,000,000 | 00,000,000 |
| Scope 2 | 144,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | - |
How Carbon Intensive is Juniper Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Juniper Pharmaceuticals, Inc.'s Location?
Juniper Pharmaceuticals, Inc.'s Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Juniper Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Juniper Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
